Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Key claim: A phase II trial is testing clofarabine plus melphalan as pre-transplant conditioning to control disease and enable donor engraftment with potentially fewer side effects than standard regimens in myelodysplasia, acute leukemia in remission, and CMML.
Abstract
This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease is in remission), or chronic myelomonocytic leukemia. Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient’s immune system from rejecting the donor’s stem cells. When the healthy stem cells from a donor are infused into a patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving clofarabine and melphalan before transplant may help prevent the cancer from coming back after transplant, and they may cause fewer side effects than standard treatment.
Why this matters
A phase II trial is testing clofarabine plus melphalan as pre-transplant conditioning to control disease and enable donor engraftment with potentially fewer side effects than standard regimens in myelodysplasia, acute leukemia in remission, and CMML.